Portfolio Detail Dura Biotech

Venture Portfolio

Dura Biotech

Some 17,000 people, mostly children and senior citizens, cannot have lifesaving heart valves implanted because the available options are too large. Dura Biotech’s key innovation is a thinner heart valve—specifically, a transcatheter aortic valve that is thirty-three percent smaller than anything on the market. Dura Biotech’s implant can be delivered through an artery in the leg rather than the heart, eliminating the need for open-heart surgery, a procedure that is risky for many patients and has a long recovery time.

Eric Sirois


CI Representative:
Patrick O’Neill
Director, Investments

back to portfolio